趋化因子受体CCR3在上皮性卵巢癌中的表达及临床意义

Expression and Clinical Significance of CCR3 in Human Epithelial Ovarian Cancer

目的:探讨趋化因子受体CCR3在上皮性卵巢癌组织中的表达情况,以及其与卵巢癌临床病理特征的关系。方法:收集上皮性卵巢癌组织、良性上皮性卵巢肿瘤组织以及正常卵巢组织标本各30例,采用多聚腺苷酸加尾实时荧光定量反转录聚合酶链反应[poly(A)-RT-qPCR]检测其CCR3的表达,并分析上皮性卵巢癌组织中CCR3的表达与患者临床病理特征之间的关系。结果:上皮性卵巢癌组织中CCR3的表达显著高于良性卵巢肿瘤组和正常卵巢组,差异有统计学意义(P<0.05);且上皮性卵巢癌组织中CCR3的表达与患者的分期、组织分级及淋巴结转移均显著相关(P<0.05)。结论:CCR3在上皮性卵巢癌组织中呈高表达,且在上皮性卵巢癌的发生和发展过程中均起着十分重要的作用。

Objective： To investigate the expression of chemokine receptor CCR3 in epithelial ovarian carcinoma, and the relationship with the clinicopathological characteristics. Methods： Tissue samples of epithelial ovarian cancer（30 cases）, benign ovarian tumor（30 cases） and normal ovarian（30 cases） were collected, the polyadenylation real-time fluorescent quantitative reverse transcription polymerase chain reaction（A [poly）-RT-qPCR] were used to detect the expression of CCR3, and analyze the correlation of CCR3 expression with the clinicopathological characteristics. Results： The expression of CCR3 in ovarian cancer group was significantly higher than those in the benign ovarian tumors and normal ovarian group（P〈0.05）, which was also markedly correlated with the staging,histological grade and lymph node metastasis of epithelial ovarian carcinoma（P〈0.05）. Conclusion： The upregulation of CCR3 expression played an important role in the development of epithelial ovarian carcinoma.